Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)
Molecular Medicine Reports · 2024
DOI: 10.3892/mmr.2024.13272 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, 2024. Verfasst von Tong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The coronavirus disease 2019 pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) seriously affected global public health security. Studies on vaccines, neutralizing antibodies (NAbs) and small molecule antiviral drugs are currently ongoing. In particular, NAbs have emerged as promising therapeutic agents due to their well‑defined mechanism, high specificity, superior safety profile, ease of large‑scale production and simultaneous application for both prevention and treatment of viral infection. Numerous NAb therapeutics have entered the clinical research stages, demonstrating promising therapeutic and preventive effects. These agents have been used for outbreak prevention and control under urgent authorization processes. The present review summarizes the molecular targets of SARS‑CoV‑2‑associated NAbs and screening and identification techniques for NAb development. Moreover, the current shortcomings and challenges that persist with the use of NAbs are discussed. The aim of the present review is to offer a reference for the development of NAbs for any future emergent infectious diseases, including SARS‑CoV‑2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.
Zitieren
APA
Zhang, T., Yang, D., Tang, L., & Hu, Y. (2024). Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13272
Vancouver
Zhang T, Yang D, Tang L, Hu Y. Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Molecular Medicine Reports. 2024. doi:10.3892/mmr.2024.13272
BibTeX
@article{Zhang2024,
author = {Zhang, Tong and Yang, Di and Tang, Liang and Hu, Yu},
title = {Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)},
journal = {Molecular Medicine Reports},
year = {2024},
doi = {10.3892/mmr.2024.13272}
}
EUVIMED